GE Healthcare Technologies Inc: CFO departs, guide reiterated -> more detail at Q2 next week

Research evidence excerpt

GE Healthcare Technologies Inc: CFO departs, guide reiterated -> more detail at Q2 next week

Global Research

23 July 2026ab

First Read

EquitiesGE Healthcare Technologies Inc

CFO departs, guide reiterated -> more detail at United States

Q2 next week Medical Supplies

12-month rating Neutral

12m price target US$67.00

What’s happened?

GEHC has announced that CFO Jay Saccaro is to leave GEHC to pursue an opportunity

outside of medtech. Mr Saccaro joined GEHC in May 2023 as CFO. The company has Price (22 Jul 2026) US$61.41

appointed an interim CFO George Newcomb who is currently Controller and Chief RIC: GEHC.O BBG: GEHC US

accounting officer.

Trading data and key metrics

What has the company said about results? 52-wk range US$88.16-59.49

Market cap. US$27.9b

The company has confirmed some unaudited numbers for Q2 including organic revenue

growth of 3.5pct which is in line with consensus. Beyond that it stated that it expects Shares o/s 454m (ORD)

adjusted EPS growth in Q2 (consensus models slight decline) but no detail to provide Free float 100%

context vs consensus and also no comment on order growth. Management has also Avg. daily volume ('000) 5,559

confirmed its reiteration of the full year guidance. Avg. daily value (m) US$350.9

Common s/h equity (12/26E) US$12.3b

What next? P/BV (12/26E) 2.3x

The company is due to report full results on Wednesday next week with investors likely Net debt to EBITDA (12/26E) 1.6x

to focus on: 1) the full results, 2) order intake growth, 3) the CFO succession plan, and 4) EPS (UBS, diluted) (USD)

the company's perspective on recently proposed China procurement reforms. 12/26E

UBS Cons.

Valuation: Q1 0.99 0.99

Our PT is DCF derived. Q2E 1.01 1.03

Q3E 1.23 1.25

Q4E 1.47 1.62

12/26E 4.69 4.87

12/27E 5.11 5.36

12/28E 5.68 5.96

Graham Doyle